The U.S. Food and Drug Administration on Friday approved the first treatment for advanced breast cancer caused by inherited mutations in BRCA genes. The agency initially approved AstraZeneca Pharmaceutical's Lynparza (olaparib tablets) in 2014 to treat advanced ovarian cancer caused by mutations in BRCA1 or BRCA2.
Federal legislation that aims to give desperately ill patients greater access to unapproved drugs reflects a broader effort to weaken medical product regulation, two University of Pennsylvania bioethicists argue in a prominent medical journal.
After reviewing the latest research, the U.S. Food and Drug Administration on Thursday reaffirmed its 2014 warning that power morcellators should rarely be used in gynecological surgery because of the small risk of spreading a hidden uterine cancer.
David Cassidy's death this week from liver failure might not have seemed such a surprise, given his well-known struggle with alcohol. But liver disease is an increasing problem in the United States, because alcohol isn't the only thing that destroys the liver, and many baby boomers who are at risk are unaware.
An experimental gene therapy that turns brain tumor cells into tiny chemotherapy factories may improve survival for patients with recurrent glioblastoma, one of the deadliest of all cancers, according to data presented Friday at a scientific meeting in Philadelphia.
Marie McCullough covers health and medicine, with a special focus on cancer and women's health issues.